Physician profile
Olivia Bennett
NPI 1275363145
$1,954.83
in general payments reported to CMS, 2019-2025
41 companies · $1,540 in 2025
The $1,540 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $415 · 2025: $1,540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,954.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $150.76 | 2024-2025 | Reblozyl |
| Janssen Biotech, INC. | $122.61 | 2024-2025 | Darzalex, Tecvayli, Talvey |
| Daiichi Sankyo INC. | $113.86 | 2025 | Enhertu, Datroway |
| Astrazeneca Pharmaceuticals LP | $106.05 | 2024-2025 | Imfinzi, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $104.27 | 2025 | Opdualag, Reblozyl |
| Merck Sharp & Dohme LLC | $101.37 | 2024-2025 | Keytruda, Lynparza |
| Lilly USA, LLC | $94.75 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Glaxosmithkline, LLC. | $83.47 | 2025 | Ojjaara |
| Legend Biotech USA INC. | $76.01 | 2024-2025 | Carvykti |
| Pfizer INC. | $71.63 | 2025 | |
| Abbvie INC. | $63.07 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.14 | 2024-2025 | Alunbrig, Ninlaro |
| Beone Medicines USA, INC. | $54.71 | 2025 | Brukinsa, Tevimbra |
| Incyte Corporation | $51.62 | 2025 | Monjuvi, Jakafi, Pemazyre |
| Adaptive Biotechnologies Corporation | $51.19 | 2025 | Clonoseq |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.